The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time. | To stir ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...